转移性黑色素瘤中的循环肿瘤DNA(ctDNA):系统综述与荟萃分析
本系统综述与荟萃分析检索2015年1月至2021年4月文献,纳入19项研究,评估ctDNA在黑色素瘤中的预后、药效动力学和预测价值。ddPCR法检测ctDNA阳性患者无进展生存期合并HR为2.10(95%CI:1.71-2.59),总生存期合并HR为2.78(95%CI:2.21-3.49),非ddPCR法结果相似。作者认为ctDNA是预测、预后和药效动力学生物标志物,临床采用前需技术标准化。
要点
- ddPCR法检测ctDNA阳性患者无进展生存期合并HR为2.10(95%CI:1.71-2.59),提示预后较差。
- ddPCR法检测ctDNA阳性患者总生存期合并HR为2.78(95%CI:2.21-3.49)。
- 治疗中连续ctDNA水平可早于影像学评估反映疗效或耐药。
核心结论
- 循环肿瘤DNA是黑色素瘤的预测、预后和药效动力学生物标志物。
- 临床采用前需要对检测方法进行技术标准化。
研究设计与样本
- 系统综述与荟萃分析,检索2015年1月至2021年4月PubMed、Cochrane Library和Ovid MEDLINE数据库。
- 纳入研究限于近5年以英文发表、在人类中评估ctDNA且患者数≥10例的研究。
- 生存数据采用合并治疗效应即对数风险比(HR)及对应标准误进行荟萃分析,遵循PRISMA声明指南。
主要发现
- 19项研究按ctDNA检测方法分组进行荟萃分析。
- 13项采用微滴数字聚合酶链反应(ddPCR)方法的研究(N=1002)中,无进展生存期合并HR为2.10(95%CI:1.71-2.59),检测到ctDNA时预后较差。
- 5项非ddPCR方法研究(N=347)中,无进展生存期合并HR为2.45(95%CI:1.29-4.63)。
- 9项ddPCR方法研究(N=841)中,总生存期合并HR为2.78(95%CI:2.21-3.49);5项非ddPCR方法研究(N=326)中,总生存期合并HR为2.58(95%CI:1.74-3.84)。
- 治疗中连续ctDNA水平显示药效动力学作用,可早于影像学评估反映疗效或耐药。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Circulating tumour DNA (ctDNA) is an emerging biomarker in melanoma. We performed a systematic review and meta-analysis to explore its clinical utility as a prognostic, pharmacodynamic (PD) and predictive biomarker. METHODS: A systematic search was conducted from Jan 2015 to April 2021, of the electronic databases PubMed, Cochrane Library and Ovid MEDLINE to identify studies. Studies were restricted to those published in English within the last 5 years, evaluating ctDNA in humans in ≥10 patients. Survival data were extracted for meta-analysis using pooled treatment effect (TE), i.e. log hazard ratios (HRs) and corresponding standard error of TE for progression-free survival or overall survival differences in patients who were ctDNA positive or negative. PRISMA statement guidelines were followed. RESULTS: A meta-analysis of 19 studies grouped according to methodology of ctDNA detection, revealed a combined estimate for HR of progression-free survival (13 studies using droplet digital Polymerase Chain Reaction (ddPCR) methodology (N = 1002) of 2.10 (95% CI: 1.71-2.59) revealing a poorer prognosis when ctDNA was detected. This result was confirmed in the smaller analysis of (non-ddPCR, N = 347) five studies: HR = 2.45 (95% CI: 1.29-4.63). Similar findings were found in the overall survival analysis of nine studies (ddPCR methodology, N = 841) where the combined HR was 2.78 (95% CI: 2.21-3.49) and of the five studies (non-ddPCR methodology, N = 326) where the combined HR was 2.58 (95% CI: 1.74-3.84). Serial ctDNA levels on treatment showed a pharmacodynamic role reflecting response or resistance earlier than radiological assessment. CONCLUSIONS: Circulating tumour DNA is a predictive, prognostic and PD biomarker in melanoma. Technical standardisation of assays is required before clinical adoption.
引用
- Gracie L, Pan Y, Atenafu EG, et al. Circulating tumour DNA (ctDNA) in metastatic melanoma, a systematic review and meta-analysis. Eur J Cancer. 2021. PMID: 34757258. doi:10.1016/j.ejca.2021.09.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。